32170 Federal Register / Vol. 74, No. 128 / Tuesday, July 7, 2009 / Notices 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism. Special 

Emphasis Panel Alcohol Pharmacotherapy 

and the Treatment and Prevention of HIV/ 

AIDS. (RFA AA 09 007/008) and Other AIDS 

Related Research. 

Date: August 6, 2009. 

Time: 8 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892. 

(Telephone Conference Call). 

Contact Person: Katrina L Foster, PhD, 

Scientific Review Officer, National Inst on 

Alcohol Abuse & Alcoholism, National 

Institutes of Health, 5635 Fishers Lane, Rm. 

2019, Rockville, MD 20852. 301–443–4032. 

katrina@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: June 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–15847 Filed 7–6–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences. Special Emphasis 

Panel Minority Biomedical Research 

Support. 

Date: July 19–20, 2009. 

Time: 7 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: Margaret J. Weidman, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 45 

Center Drive, Room 3AN18B, Bethesda, MD 

20892. 301–594–3663. 

weidmanma@nigms.nih.gov. 

Name of Committee: National Institute of 

General Medical Sciences. Special Emphasis 

Panel MBRS Score. 

Date: July 20–21, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: Lisa Dunbar, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 45 

Center Drive, Room 3AN12, Bethesda, MD 

20892. 301–594–2849. dunbarl@mail.nih.gov. 

Name of Committee: National Institute of 

General Medical Sciences. Special Emphasis 

Panel New Innovator Awards. 

Date: July 21, 2009. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892. (Telephone Conference Call). 

Contact Person: Richard T. Okita, PhD, 

Program Director, Pharmacological and 

Physiological Sciences Branch, National 

Institute of General Medical Sciences, 

National Institutes of Health, Natcher 

Building, Room 2A5–49, Bethesda, MD 

20892. 301–594–4469. okitar@nigms.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: June 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–15846 Filed 7–6–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Health Guidelines 

for Human Stem Cell Research 

SUMMARY: The National Institutes of 

Health (NIH) is hereby publishing final 

‘‘National Institutes of Health 

Guidelines for Human Stem Cell 

Research’’ (Guidelines). 

On March 9, 2009, President Barack 

H. Obama issued Executive Order 

13505: Removing Barriers to 

Responsible Scientific Research 

Involving Human Stem Cells. The 

Executive Order states that the Secretary 

of Health and Human Services, through 

the Director of NIH, may support and 

conduct responsible, scientifically 

worthy human stem cell research, 

including human embryonic stem cell 

(hESC) research, to the extent permitted 

by law. 

These Guidelines implement 

Executive Order 13505, as it pertains to 

extramural NIH-funded stem cell 

research, establish policy and 

procedures under which the NIH will 

fund such research, and helps ensure 

that NIH-funded research in this area is 

ethically responsible, scientifically 

worthy, and conducted in accordance 

with applicable law. Internal NIH 

policies and procedures, consistent with 

Executive Order 13505 and these 

Guidelines, will govern the conduct of 

intramural NIH stem cell research. 

DATES: Effective Date: These Guidelines 

are effective on July 7, 2009. 

Summary of Public Comments on 

Draft Guidelines: On April 23, 2009 the 

NIH published draft Guidelines for 

research involving hESCs in the Federal 

Register for public comment, 74 FR 

18578 (April 23, 2009). The comment 

period ended on May 26, 2009. 

The NIH received approximately 

49,000 comments from patient advocacy 

groups, scientists and scientific 

societies, academic institutions, medical 

organizations, religious organizations, 

and private citizens. The NIH also 

received comments from members of 

Congress. This Notice presents the final 

Guidelines together with the NIH 

response to public comments that 

addressed provisions of the Guidelines. 

Title of the Guidelines, Terminology, 

and Background 

Respondents felt the title of the NIH 

draft guidelines was misleading, in that 

it is entitled ‘‘National Institutes of 

Health Guidelines for Human Stem Cell 

Research,’’ yet addresses only one type 

of human stem cell. The NIH notes that 

although the Guidelines pertain 

primarily to the donation of embryos for 

the derivation of hESCs, one Section 

also applies to certain uses of both 

hESCs and human induced pluripotent 

stem cells. Also, the Guidelines discuss 

applicable regulatory standards when 

research involving human adult stem 

cells or induced pluripotent stem cells 

constitutes human subject research.